BioMedical Materials program
BMM is a public-private partnership of the Dutch government, academia and industry that focuses on research and development in the field of biomedical materials. Over the next five years BMM aims to become a world leader in the field of biomedical materials and their use and applications in a clinical environment.
The BioMedical Materials program will address four priority disease areas, each addressing specific clinical needs and specific biomedical materials breakthroughs:
- cardiovascular diseases (incl. consequences of diabetes),
- oncology (cancer),
- musculoskeletal, and
- nephrology.
New concepts will be explored in a translational approach, where ideas will be tested from the lab up to and including the proof-of-principle, involving all partners, disciplines and areas of expertise that are required for application in a clinical environment.
The clinical need for new therapies will be leading in defining the focus in the research agenda and research topics. A total of around 28 partners have committed themselves to this initiative. These include private companies, varying from large companies (Fujifilm Life Science, Medtronic, Organon, Philips, DSM), through medium sized companies amongst which Fortimedix, to small, start-up companies, as well as leading universities and university medical centers (UMC’s) in the Netherlands and knowledge institutes such as TNO.
A full list of partners and supporters and more information on BMM can be found on www.biomedicalmaterialsprogram.nl
